KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Gains from Sales and Divestitures (2016 - 2017)

Historic Gains from Sales and Divestitures for Emergent BioSolutions (EBS) over the last 8 years, with Q3 2017 value amounting to $413752.0.

  • Emergent BioSolutions' Gains from Sales and Divestitures changed N/A to $413752.0 in Q3 2017 from the same period last year, while for Sep 2017 it was $413752.0, marking a year-over-year change of. This contributed to the annual value of $422515.0 for FY2015, which is 1703.69% up from last year.
  • Per Emergent BioSolutions' latest filing, its Gains from Sales and Divestitures stood at $413752.0 for Q3 2017.
  • In the past 5 years, Emergent BioSolutions' Gains from Sales and Divestitures ranged from a high of $422515.0 in Q4 2015 and a low of $291619.0 during Q1 2013
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $353117.0 (2016), whereas its average is $360015.9.
  • As far as peak fluctuations go, Emergent BioSolutions' Gains from Sales and Divestitures surged by 143483.68% in 2013, and later soared by 235.58% in 2014.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Gains from Sales and Divestitures stood at $337498.0 in 2013, then grew by 6.97% to $361010.0 in 2014, then grew by 17.04% to $422515.0 in 2015, then decreased by 4.24% to $404585.0 in 2016, then grew by 2.27% to $413752.0 in 2017.
  • Its Gains from Sales and Divestitures was $413752.0 in Q3 2017, compared to $404585.0 in Q2 2016 and $353117.0 in Q1 2016.